Other Clinical Trial - A Study of Lenvatinib (MK-7902) in Pediatric

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response.

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT02963610` - Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer	Phase 1/Phase 2
	Completed	`NCT01778439` - A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors	Phase 1

NCT number	NCT04447755
Study type	Interventional
Source	Merck Sharp & Dohme LLC
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	July 30, 2020
Completion date	February 19, 2025

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) — E7080-G000-231

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms